Abstract
Case reports are presented for three patients with metastatic breast cancer who received first-line treatment with bevacizumab in combination with taxanes in clinical trials. Two patients showed peak reductions in lesion size of 49 and 70%, respectively. In one patient, subsequent treatment with bevacizumab in combination with capecitabine [Xeloda (after discontinuation of paclitaxel due to asthenia)] yielded peak reductions in target lesion size of 78%. One patient experienced a progression-free survival time of 16 months. In all three patients, bevacizumab was well tolerated and mostly displayed only mild toxicities.
MeSH terms
-
Antibodies, Monoclonal / administration & dosage*
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bevacizumab
-
Bone Neoplasms / radiotherapy
-
Bone Neoplasms / secondary
-
Bone Neoplasms / surgery
-
Breast Neoplasms / drug therapy*
-
Breast Neoplasms / pathology
-
Breast Neoplasms / radiotherapy
-
Breast Neoplasms / surgery
-
Capecitabine
-
Carcinoma in Situ / drug therapy*
-
Carcinoma in Situ / pathology
-
Carcinoma in Situ / radiotherapy
-
Carcinoma in Situ / surgery
-
Carcinoma, Ductal / drug therapy*
-
Carcinoma, Ductal / pathology
-
Carcinoma, Ductal / radiotherapy
-
Carcinoma, Ductal / secondary*
-
Carcinoma, Ductal / surgery
-
Combined Modality Therapy
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / adverse effects
-
Deoxycytidine / analogs & derivatives
-
Disease-Free Survival
-
Female
-
Fluorouracil / administration & dosage
-
Fluorouracil / adverse effects
-
Fluorouracil / analogs & derivatives
-
Humans
-
Kidney Neoplasms / radiotherapy
-
Kidney Neoplasms / secondary
-
Kidney Neoplasms / surgery
-
Liver Neoplasms / radiotherapy
-
Liver Neoplasms / secondary
-
Liver Neoplasms / surgery
-
Lung Neoplasms / radiotherapy
-
Lung Neoplasms / secondary
-
Lung Neoplasms / surgery
-
Lymphatic Metastasis
-
Paclitaxel / adverse effects
-
Survival Analysis
-
Taxoids / administration & dosage
-
Treatment Outcome
-
Vascular Endothelial Growth Factor A / antagonists & inhibitors
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Taxoids
-
Vascular Endothelial Growth Factor A
-
Deoxycytidine
-
Bevacizumab
-
Capecitabine
-
Paclitaxel
-
Fluorouracil